Navigation Links
Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 11, 2007 - Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, announced today that several abstracts covering preclinical work with romidepsin will be presented at the 2007 Annual Meeting of the American Association of Cancer Research taking place in Los Angeles, CA April 14-18, 2007. These presentations will focus on a variety of preclinical research performed by multiple academic collaborators of the Company. Full text of the abstracts can be viewed on the American Association of Cancer Research website at www.aacr.org.

The presentation schedule of selected abstracts is as follows:

Abstract #689 "Oncogenic H-ras facilitates apoptosis induced by histone deacetylase inhibitors in human urinary bladder cancer cells" will be presented in a poster session Sunday, April 15 from 8:00 am - 12:00 pm. Dr. Shambhunath Choudhary et al of the University of Tennessee are authors.

Abstract #1835 "The HDAC inhibitors romidepsin and PXD101 interact synergistically with Bortezomib in human chronic lymphomocytic leukemia (CLL) cells in association with NF-kB inactivation" will be presented in a poster session on Monday, April 16 from 8:00 am - 12:00 pm. Dr. Yun Dai et al of the Virginia Commonwealth University and Massey Cancer Center are authors.

Abstract #2484 "Histone deacetylase inhibitor FK228 enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines" will be presented in an oral session on Monday April 16 from 11:55 am - 12:10 pm. Dr. Wei Zhang et al of the UT Southwestern Medical Center are authors.

Abstract #3524 "Translational studies of depsipeptide (romidepsin, FK228) a histone deacetylase (HDAC) inhibitor, in patients with head and neck cancer" will be presented in a poster session on Tuesday April 17 from 8:00 am - 12:00 pm. Dr. Missak Haigentz Jr. et al of the Albert Einstein College of M edicine, the Dana-Farber Cancer Institute and National Cancer Institute/CTEP are authors.

About Romidepsin

Romidepsin is a novel agent in a new class of anti-cancer drugs known as histone deacetylase inhibitors. The Company is conducting a pivotal phase II study of romidepsin for patients with cutaneous T-cell lymphoma (CTCL) and has initiated a pivotal phase II study for patients with peripheral T-cell lymphoma (PTCL). Romidepsin has received Orphan Drug Designation from the Food and Drug Administration (FDA) for the treatment of non-Hodgkin T-cell lymphomas, which includes CTCL and PTCL. In addition, the European Agency for the Evaluation of Medicinal Products (EMEA) has issued Orphan Drug status for the treatment of both CTCL and PTCL. Fast Track status for CTCL has also been designated by the FDA. Romidepsin is in clinical trials for a variety of other hematological malignancies and solid tumors, including hormone refractory prostate cancer, pancreatic cancer and multiple myeloma. These trials and others are being conducted by the Company or the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with the Company.

About Gloucester Pharmaceuticals, Inc.

Gloucester Pharmaceuticals, Inc. is a privately-held, venture-backed company that develops and commercializes innovative products for the treatment of cancer patients. Gloucester is headquartered in Cambridge, MA. For more information on Gloucester and our clinical development program visit our website at www.gloucesterpharma.com or call 888-474-2825.

Contact

Media
KMorrisPR
Kathryn Morris, 845-635-9828
kathryn@kmorrispr.com
or
Gloucester Pharmaceuticals
Beverly Holley, 617-583-1362
beve rly.holley@gloucesterpharma.com


'"/>




Related medicine technology :

1. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
2. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
3. Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/18/2017)... Pa. and KALAMAZOO, Mich. , Sept. 18, ... , and OptiMed Specialty Pharmacy of ... to offer a strategic hub service that expedites and ... sought-after personal spirometer, Spiro PD 2.0, and wellness management ... spirometer is a medical device used to measure lung ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
Breaking Medicine News(10 mins):